Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients

  • STATUS
    Recruiting
  • participants needed
    200
  • sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
Updated on 25 October 2022
antibiotic therapy
antibiotics
diarrhea
chest x-ray
lidocaine
x-rays
vaccination
cough
inhalational anthrax
anthrax vaccine adsorbed
spinning
gastrointestinal anthrax
septicemia
lymph node biopsy

Summary

This study will examine pathophysiology and immune response of anthrax in infected or exposed individuals to learn more about the disease symptoms, prevention and response to treatment. In addition, it will evaluate immune response to the anthrax vaccine AVA (Anthrax Vaccine Adsorbed) in healthy, non-infected individuals.

The following individuals may be eligible for this study:

  1. People with confirmed or suspected anthrax (inhalational, cutaneous or gastrointestinal, either acute or recovering);
  2. People exposed to anthrax who have no clinical symptoms.
  3. Healthy people who have not been exposed to anthrax and have been vaccinated with AVA.

Those enrolled in the study will undergo the following tests and procedures.

Infected and exposed individuals:

  • Symptomatic participants will have the following clinical procedures if medically
    necessary
  • a) blood tests for cell counts, chemistries and evidence of anthrax bacteria;
  • b) nasal swab to test for evidence of anthrax
  • c) chest X-ray;
  • d) computed tomography (CT) scan (special X-rays to examine the lungs or abdomen);
  • e) echocardiogram to examine the heart
  • f) magnetic resonance imaging (MRI), a special imaging test using a magnetic field and radio waves to examine the infected area of skin and soft tissue for patients with cutaneous anthrax.
  • All subjects (with or without symptoms) will have the following research procedures:
  • a) blood tests to examine immune response to anthrax;
  • b) throat swab to test for evidence of anthrax
  • c) nasopharyngeal wash to test for anthrax. Water is sprayed into the nostrils and then allowed to drain for collection in a cup;
  • d) induced sputum to test for presence of and immune response to anthrax. A mask with a saline mist is placed over the subject s mouth and nose, causing the subject to cough and produce sputum from the lungs. The sputum is collected in a cup this is for individuals 18 and older who do not undergo bronchoscopy, described below.
  • Participants 18 years of age and older may have the following optional research
    procedures
  • a) leukapheresis or plasmapheresis (see description under non-infected, vaccinated individuals above);
  • b) lymph node biopsy. A sample of lymph node tissue is surgically removed under local anesthetic;
  • c) bronchoalveolar lavage. This 15- to 30-minute procedure is done in the intensive care unit. The mouth, nasal passages, throat and airways are numbed with lidocaine and a thin flexible tube is passed through the nose into the lung airways. Samples of cells and secretions are obtained by rinsing (lavage) the airways with salt water. The fluid is analyzed for infection, inflammatory cells and inflammatory chemicals.

All infected and exposed individuals will have periodic medical history and physical exam evaluations and be offered treatment or prophylaxis (treatment to prevent infection) with antibiotics, according to the guidelines of the Centers for Disease Control and Prevention (CDC). Patients will be monitored for at least 24 months after antibiotic treatment, or longer if circumstances warrant.

Non-infected, vaccinated individuals

  1. medical history and physical examination
  2. blood tests-- between 10 and 50 ml (2-10 teaspoons) of blood will be drawn at a time, and not more than 450 ml will be taken in a 6-week period. Based on the blood test results, other optional research procedures may be requested
  3. leukapheresis to collect white blood cells and plasmapheresis to collect plasma (the liquid part of the blood). For both of these procedures, blood is collected through a needle placed in an arm vein. The blood flows into a special machine that separates it into its components by spinning. The desired components (white cells or plasma) are removed and the rest of the blood is returned to the body through the same needle or a second needle in the other arm.

...

Description

The intentional use of Bacillus anthracis in 2001 as a bioterrorism weapon with fatal consequences renewed interest in past epidemiologic and animal research about pathogenesis and posed new dilemmas about diagnosis and treatment. Cases in the October 2001 US outbreak were theoretically exposed via one dispersal method: aerosolization of Ames strain spores. While some developed the cutaneous anthrax form, others sustained the more serious inhalational disease. Inhaled spores are known to travel to alveolar macrophages and then onto the mediastinal lymph nodes where germination to the bacterium form and toxin release are thought to occur. Infective dose, significance of dormant spores after long-term antibiotic therapy, spectrum of disease and even precise cause of death remain unknown. This observational, prospective natural history study was developed during the 2001 outbreak and is set up to follow participants from the time of exposure through post-recovery (greater than ten years). Healthy vaccinated participants have been included to evaluate serum titers and cell markers in relation to dose and frequency of Anthrax Vaccine Adsorbed (AVA) vaccine.

Details
Condition Anthrax, Bacillus Infections
Clinical Study IdentifierNCT00050310
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last Modified on25 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Subjects at least 3 years old, including pregnant women, are eligible for inclusion if they
meet one of the five criteria listed below, are hemodynamically and clinically stable, and
agree to stored samples. Women of child-bearing age or potential will not be excluded from
participation but pregnancy status will be determined by serum or urine pregnancy test at
time of enrollment in order to optimize subsequent evaluation and care
Although the study is open to participants at least 3 years old, pediatric anthrax cases
Inhalation Anthrax (acute or recovering infection)
are historically rare and essentially of the cutaneous type. Therefore, few, if any
CONFIRMED
-nonspecific febrile illness followed by sepsis and/or respiratory failure
pediatric subjects are expected
Decisionally impaired subjects will be included in this study only if a Legally Authorized
AND
-B anthracis isolation (via culture) from any site OR 2 supportive lab tests
Representative (LAR) understands and is willing to sign a written informed consent
document
OR SUSPECTED
-nonspecific febrile illness followed by sepsis and/or respiratory failure with no
alternative diagnosis
AND
-one supportive lab test OR direct epidemiological link to a confirmed environmental
exposure
Cutaneous Anthrax (acute or recovering infection)
CONFIRMED
-characteristic lesion (papule->vesicular->depressed black eschar plus or minus
AND
-B anthracis isolation (culture) from any site OR 2 supportive lab tests
SUSPECTED
-Characteristic lesion with no alternative diagnosis
AND
-one supportive lab test OR direct epidemiological link to a confirmed environmental
edema, erythema, necrosis, or ulceration)
exposure
Gastrointestinal Anthrax (acute or recovering infection)
CONFIRMED
-Severe abdominal pain often associated with bloody vomiting/diarrhea followed by
fever/septicemia
AND
-B anthracis isolation (culture) from any site OR 2 supportive lab tests
SUSPECTED
-Severe abdominal pain often associated with bloody vomiting/diarrhea followed by
fever/septicemia with no alternative diagnosis
AND
-1 supportive lab test OR direct epidemiological link to a confirmed environmental
exposure
These definitions were subsequently updated by the CDC in 2010 to accept clinically
compatible symptoms plus one of the following: a positive culture, a positive
immunohistochemical stain for antigen, a 4-fold increase in anti-PA IgG or a positive
documented exposure with detection of DNA via PCR (26)
Exposed individuals who are clinically asymptomatic
Past or imminent vaccination in healthy (non-anthrax exposed)
Hemodynamically and clinically stable at time of evaluation at NIH
Hemodynamically: stable vital signs
Clinically: no obvious signs of disease progression (e.g. worsening pleural
effusions or increasing cutaneous edema)
acute/newly recovered patients must be receiving standard antimicrobial therapy
Participant agrees to stored samples

Exclusion Criteria

Inability of subject or Legally Authorized Representative (LAR) to understand or subject
not willing to sign a written informed consent document
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note